Device therapy of ventricular tachyarrhythmias

Area of Science:

• Cardiology
• Biomedical Engineering
• Electrophysiology

Background:

• Device therapy is crucial for managing life-threatening ventricular arrhythmias.
• Current options include antitachycardia pacemakers, endovascular cardioverters (experimental), and the commercially available Automatic Implantable Cardioverter-Defibrillator (AICD).

Purpose of the Study:

• To review the current status and future directions of device therapy for ventricular arrhythmias.
• To highlight the importance of patient selection and evaluation for successful device implantation.

Main Methods:

• Review of existing literature on device therapy for ventricular arrhythmias.
• Analysis of the capabilities and limitations of current antitachycardia and defibrillator devices.
• Discussion of drug-device interactions and future technological advancements.

Main Results:

• Antitachycardia pacemakers and cardioverters have limitations, including potential tachycardia acceleration and lack of defibrillation.
• The AICD is commercially available but requires careful patient selection.
• Most patients require concomitant antiarrhythmic drug therapy, with unique drug-device interactions.

Conclusions:

• Successful device therapy for ventricular arrhythmias necessitates thorough preimplantation evaluation and patient selection.
• Future antitachycardia devices are expected to be sophisticated, easily implantable, and programmable, integrating features of current devices.